Krsnaa Diagnostics
Stock Snapshot
Price Performance
Vista Outlook
View Technicals Analysis →Basis of our Recommendation
Krsnaa Diagnostics is strategically transitioning from a government-focused PPP model to a hybrid approach that emphasizes retail expansion, which is expected to significantly enhance revenue growth and profitability. Management's confidence in scaling their integrated radiology and pathology services, alongside the operationalization of the Rajasthan PPP project, underpins Vista's forecast of accelerating revenue growth and improving margins. The company's dual-engine growth strategy, leveraging existing infrastructure to support retail operations, positions it well to capture market share in a fragmented industry characterized by rising healthcare demand. However, execution risks related to project timelines and competitive pressures remain critical watchpoints. The macroeconomic environment in India, marked by stable inflation and favorable liquidity conditions, supports the healthcare sector's growth trajectory. Over the next 12-24 months, Krsnaa's focus on expanding its retail footprint and enhancing operational efficiency will be pivotal in navigating potential headwinds such as administrative delays and margin pressures. Overall, while the outlook remains cautiously optimistic, investors should monitor the execution of strategic initiatives closely
Why We Like This Stock
- Transition to a hybrid model focusing on retail expansion is expected to drive significant revenue growth
- Management's confidence in operationalizing the Rajasthan PPP project supports margin improvement
- The dual-engine growth strategy leverages existing infrastructure to enhance profitability
Things To Watch Out For
- Execution risks related to project timelines and scaling retail operations could impact growth
- Potential administrative delays in government payments may pressure cash flow
- Competitive landscape in the diagnostics sector poses challenges to market share capture
Key Parameters
Financial Snapshot
| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 590 | 682 | 691 | 864 | 996 |
| Profit Before Tax (Cr.) | 72 | 105 | 132 | 133 | 163 |
| PBT Margin | 12.2% | 15.5% | 1910.3% | 15.4% | 16.4% |
| Net Profit (Cr.) | 61 | 83 | 107 | 108 | 133 |
| Earnings Per Share | 18.7 | 25.7 | 33.1 | 33.3 | 40.9 |
Analyst Recommendations
| Broker | Recommendation | Target Price | Date |
|---|---|---|---|
| Moneycontrol | ▲ Overweight | — | 08-Jul-2026 |
Company Overview
Show Company Profile
Krsnaa Diagnostics Limited provides diagnostic services in India. It offers a range radiology services, including computed tomography scans, magnetic resonance imaging, X-rays, and ultrasound and advanced imaging; pathology services, such as laboratory, and home collection and preventive health; and teleradiology and telepathology services. The company also provides other diagnostics services, such as ophthalmic test, mammography, dental imaging, stress test, dual-energy X-ray absorptiometry scan, and bone mineral density test. It serves individual patients, government clients, corporate clients, hospitals, clinics, private practitioner, and other healthcare providers. Krsnaa Diagnostics Limited was incorporated in 2010 and is based in Pune, India.